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Rethinking the assessment of risk of bias
due to selective reporting: a cross-sectional
study
Matthew J. Page1,2* and Julian P. T. Higgins1
Abstract
Background: Selective reporting is included as a core domain of Cochrane’s tool for assessing risk of bias in
randomised trials. There has been no evaluation of review authors’ use of this domain. We aimed to evaluate
assessments of selective reporting in a cross-section of Cochrane reviews and to outline areas for improvement.
Methods: We obtained data on selective reporting judgements for 8434 studies included in 586 Cochrane reviews
published from issue 1–8, 2015. One author classified the reasons for judgements of high risk of selective reporting
bias. We randomly selected 100 reviews with at least one trial rated at high risk of outcome non-reporting bias
(non-/partial reporting of an outcome on the basis of its results). One author recorded whether the authors of these
reviews incorporated the selective reporting assessment when interpreting results.
Results: Of the 8434 studies, 1055 (13 %) were rated at high risk of bias on the selective reporting domain. The
most common reason was concern about outcome non-reporting bias. Few studies were rated at high risk because
of concerns about bias in selection of the reported result (e.g. reporting of only a subset of measurements, analysis
methods or subsets of the data that were pre-specified). Review authors often specified in the risk of bias tables the
study outcomes that were not reported (84 % of studies) but less frequently specified the outcomes that were partially
reported (61 % of studies). At least one study was rated at high risk of outcome non-reporting bias in 31 % of reviews.
In the random sample of these reviews, only 30 % incorporated this information when interpreting results, by
acknowledging that the synthesis of an outcome was missing data that were not/partially reported.
Conclusions: Our audit of user practice in Cochrane reviews suggests that the assessment of selective reporting
in the current risk of bias tool does not work well. It is not always clear which outcomes were selectively reported
or what the corresponding risk of bias is in the synthesis with missing outcome data. New tools that will make it
easier for reviewers to convey this information are being developed.
Keywords: Bias, Quality, Methodology, Randomised trials, Systematic reviews
Background
Reports of randomised trials should provide a complete
and balanced account of the findings. However, many
reports are plagued by selective reporting [1]. One type
of selective reporting, which we call “outcome non-
reporting bias”, occurs when some outcomes that were
measured and analysed are not reported or are partially
reported based on the nature of the results (e.g. statistical
significance or magnitude of effect) [2]. For example, par-
ticipant deaths may be counted and compared between
intervention groups but trialists present no data because
the effect favoured the comparator or only state that the
between-group difference was not statistically significant;
in this case, the summary statistics needed to include the
trial in a meta-analysis are unavailable [3, 4]. Another type
of selective reporting, which we call “bias in selection of
the reported result”, occurs when the effect estimate that
is fully reported in a publication has been selected from
among multiple measurements or analyses (e.g. trialists
perform multiple adjusted analyses yet only report that
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which yielded the most favourable effect estimate) [5].
Given the frequency with which both types of selective
reporting occur [4, 6, 7], authors of systematic reviews are
encouraged to assess these sources of bias in the included
studies.
Selective reporting is included as one of the core
domains of the Cochrane tool for assessing the risk of
bias in randomised trials (RoB tool) [8]. The domain was
included in the tool when it was created in 2006, in
response to emerging evidence of worrying degrees of
selective reporting [3, 9]; at that time, no existing risk of
bias tool addressed the issue. Review authors were asked
to judge the risk of selective reporting bias as either low
risk, high risk or unclear risk and to provide reasons for
their judgements. Guidance for a judgement of high risk
of bias, as specified in the Cochrane Handbook [10], is
presented in Table 1. These criteria include examples of
outcome non-reporting bias and bias in selection of the
reported result.
Limitations of the assessment of selective reporting in
the current RoB tool were recognised in an evaluation of
the tool [11]. The problems arise mainly from the fact
that assessments are conducted at the study-level, which
has the following three implications:
1. All findings from a study are considered at high risk
of bias on the basis that one or more outcomes are
not/partially reported. However, it makes little sense
to judge the fully reported outcomes in such trials at
high risk of bias by default.
2. Review authors may judge a study at high risk of
selective reporting bias but not declare in the RoB
table the specific outcomes that were selectively
reported (e.g. only state “Some outcomes were not
reported”). This prevents readers from knowing which
outcomes of the review should be interpreted with
caution.
3. Outcome non-reporting bias and bias in selection of
the reported result are considered simultaneously,
which is not ideal because each has different
consequences. Outcome non-reporting bias in one
or more trials can put the treatment effect estimate
of a systematic review/meta-analysis which cannot
include the data at risk of bias [2, 12]. This is
analogous to publication bias, whereby a whole
study is inaccessible to review authors on the basis
of the results. In contrast, bias in selection of the
reported result puts effect estimates from individual
primary studies at risk of bias in the same way as
other domains in the RoB tool (e.g. attrition bias,
detection bias), as well as putting the systematic
review/meta-analytic effect estimate at risk of bias.
An example of this distinction is presented in Fig. 1.
In this example, there is a high risk of bias in selection
of the reported result for depression because
depression was measured and analysed in multiple
ways, yet only the most favourable of all possible
effect estimates was reported. Inclusion of this effect
estimate can bias the corresponding meta-analysis of
depression. In contrast, anxiety was measured and
analysed but no data were reported because the
results were unfavourable; this does not bias the trial,
but it can lead to outcome non-reporting bias in the
meta-analysis of anxiety which cannot include the
unreported data from this trial. As another example, a
trialist may measure blood glucose at 3 and
6 months, yet only report the 3-month data on the
basis of its large, favourable result. In this instance,
a meta-analysis of 3-month data includes trial data
at high risk of bias in selection of the reported
result, while a meta-analysis of 6-month data which
cannot include the non-reported data from this trial
is at high risk of outcome non-reporting bias.
Another limitation of the current RoB tool is that it
lacks clear guidance on how to incorporate the assess-
ment of outcome non-reporting bias into the interpret-
ation a systematic review effect estimate.
To date, there has been no evaluation of Cochrane re-
view authors’ use of the selective reporting domain in the
current RoB tool. It is unclear how many studies are rated
at low/unclear/high risk of selective reporting bias and
what reasons are provided for the judgements; whether re-
view authors specify the outcomes they suspect have been
selectively reported, which readers need to determine
which of the trial and review outcomes are problematic;
and whether review authors acknowledge the risk of se-
lective reporting bias in the synthesis when interpreting
the results (e.g. state that a particular meta-analysis is
missing studies with inaccessible outcome data).
The aim of this study is to evaluate the assessments of
risk of bias due to selective reporting in a cross-section
of Cochrane reviews, so as to inform the development of
a revised tool.
Table 1 Criteria for a judgement of high risk of bias due to
selective reporting in the Cochrane risk of bias tool for
randomised trials (2011 version)
Any one of the following: (1) not all of the study’s pre-specified
primary outcomes have been reported; (2) one or more outcomes
of interest in the review are reported incompletely so that they
cannot be entered in a meta-analysis; (3) the study report fails to
include results for a key outcome that would be expected to have
been reported for such a study; (4) one or more primary outcomes
is reported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified, or; (5) one or more
reported primary outcomes were not pre-specified (unless clear
justification for their reporting is provided, such as an unexpected
adverse event). We consider criteria 1–3 examples of outcome non-
reporting bias and criteria 4–5 examples of bias in selection of the
reported result.
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Methods
Eligibility criteria
We included Cochrane reviews meeting the following
criteria:
 review of a therapeutic or preventive intervention;
 published between issue 1 to 8, 2015, in the
Cochrane Database of Systematic Reviews (CDSR)
as a new, updated or amended review;
 included an assessment of selective reporting in the
included studies using the RoB tool.
We excluded review protocols and reviews of method-
ology, diagnostic test accuracy and prognostic studies,
because selective reporting is not a standard risk of bias
domain in these reviews.
Data source
All Cochrane reviews are prepared as RevMan files
[13] which are stored in Archie, a database managed
by the Cochrane Informatics and Knowledge Manage-
ment Department (IKMD). In September 2015, the
IKMD provided us with the selective reporting judge-
ment (low risk, unclear risk or high risk) and support-
ing text for the judgement, extracted from Archie, for
all studies in reviews meeting our eligibility criteria.
The IKMD also provided the title, DOI, issue number,
year of publication and Cochrane Review Group of
each review. Data were supplied in a Microsoft Excel®
file.
Data extraction and classification
We categorised the supporting text of each trial rated at
high risk of bias due to selective reporting. Text was ini-
tially classified under one of the five criteria specified in
the Cochrane Handbook (outlined in the Table 1), or as
“other” if it did not meet those criteria. New categories
were subsequently generated for all “other” reasons using
an iterative approach. That is, category labels were gener-
ated and sometimes amended when a new example was
encountered, to ensure that all categories were mutually
exclusive. Whenever a category label was amended, all
previous classifications were reviewed and modified as
appropriate.
In addition, we recorded the specific outcome(s) that
were reported as having been selectively reported (e.g.
“all-cause mortality”, “pain”, “adverse events”). Instances
where review authors did not specify the outcome
(e.g. only included a statement such as “Not all pre-
specified outcomes were reported”) were recorded as
“Not specified”.
We drew a random sample of 100 reviews with at least
one trial rated at high risk of outcome non-reporting
bias (i.e. non- or partial reporting of an outcome) using
the random number generator in Microsoft Excel®. We
extracted from each review the following: total number
of included studies; number of studies at high risk of
outcome non-reporting bias; specific outcomes rated at
high risk of outcome non-reporting bias (as determined
from the RoB tables); the reviewer-perceived import-
ance of the outcome(s) at high risk of outcome non-
reporting bias (i.e. “primary” or “secondary”); and whether
Fig. 1 Distinction between outcome non-reporting bias and bias in selection of the reported result
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a meta-analysis was performed on at least one of the out-
come(s) at high risk of outcome non-reporting bias.
We then examined the main text (“Effect of interven-
tions” section), abstract and Summary of Findings table
of each review and recorded whether or not review
authors acknowledged that a synthesis of an outcome
was missing data that were not/partially reported (e.g.
stated that the data from two studies which measured a
particular outcome were not reported and hence could
not be included in the meta-analysis of that outcome).
By “synthesis” we mean either a narrative synthesis/
summary or meta-analysis of the results. We also re-
corded whether review authors used any of the following
statistical methods to explore whether a meta-analysis was
robust to outcome non-reporting bias: the bound for out-
come non-reporting bias developed by Williamson et al.
[14], the multivariate meta-analysis approach developed
by Kirkham et al. [15], or the model-based correction
developed by Copas et al. [16]. All data extraction and
classification was undertaken by one author (MJP).
Statistical analyses
The analysis was mostly descriptive, with dichotomous
variables (e.g. trial rated at high risk of bias or not)
summarised using frequencies and percentages and
continuous variables (e.g. number of included trials per
review) summarised using medians with interquartile
ranges (IQRs). We used the chi-squared test for differ-
ences in proportions to explore whether acknowledge-
ments that data were missing from the synthesis of an
outcome differed according to reviewer-perceived im-
portance of the outcome.
Results
Characteristics of included reviews and trials
We examined 586 reviews including 8434 studies. Reviews
included a median of eight studies (IQR 4–16), and
addressed a wide range of topics, with 50 Cochrane Re-
view Groups contributing at least one review to the sam-
ple. The median number of reviews per Cochrane Review
Group was eight (IQR 4–15) (Additional file 1: Table S1).
Of the 8434 included studies, the selective reporting
domain was rated as low risk in 4473 (53 %), unclear risk
in 2906 (34 %) and high risk in 1055 (13 %). Of the 586
reviews, 239 (41 %) included at least one study rated at
high risk of selective reporting bias. In these 239 reviews,
a median of 20 % (IQR 10–40 %) of the studies per review
were rated at high risk of selective reporting bias.
Reasons for high risk of selective reporting bias
Across the 1055 studies rated at high risk of selective
reporting bias, we identified 89 different reasons provided
by review authors to support their judgement. These were
classified under nine categories (Table 2; all reasons are
listed in Additional file 1: Table S2). The most common
reason was concern about outcome non-reporting bias,
which was recorded in 819/1055 (78 %) studies. Less com-
mon reasons included concern about the documents avail-
able for assessment (e.g. “no protocol available”) (59/1055
[6 %]), reporting of only a subset of measurements, ana-
lysis methods or subsets of the data (e.g. subscales) that
were pre-specified (58/1055 [6 %]), and post hoc reporting
of outcomes, measurements, analysis methods or subsets
of the data (56/1055 [5 %]). We considered a small pro-
portion of review authors’ reasons to be irrelevant to the
selective reporting domain (73/1055 [7 %]); for example,
authors stated that not all randomised participants were
included in the analysis or that blinding of participants
was unclear. The reason for the high-risk judgement was
considered unclear for 69/1055 (7 %) studies (e.g. review
authors stated that “All outcomes were reported”).
Review authors did not always describe in the RoB
table the specific outcome that was selectively reported.
Of the 387 studies rated at high risk due to non-
reporting, the non-reported outcome was specified in
326 (84 %). Of the 364 studies rated at high risk due to
partial reporting, the partially reported outcome was
specified in 222 (61 %). And of the remaining studies
rated at high risk due to another reason (n = 571), the
outcome of concern was specified for only 282 (49 %).
Acknowledging missing data in the synthesis of an
outcome
At least one study was rated at high risk of outcome
non-reporting bias in 181/586 (31 %) reviews; we exam-
ined a random sample of 100 of these reviews. The 100
reviews addressed various health conditions managed
by 33 of the 50 Cochrane Review Groups (Additional
file 1: Table S1). A median of 20 % (IQR 10–40 %) of
the studies per review were rated at high risk of outcome
non-reporting bias (Table 3). In 79 (79 %) reviews, the
outcomes that were not/partially reported were specified
in the RoB tables; 27 reviews clearly described one out-
come that was not/partially reported while 52 described
more than one outcome. At least one of the non-/partially
reported outcomes was considered a primary review out-
come in 52/79 (66 %) reviews. In addition, in 51/79 (65 %)
reviews, a meta-analysis was performed on at least one
outcome that was not/partially reported in some studies
(using data from studies that completely reported the
outcome).
We were unable to assess whether authors of 21 reviews
acknowledged that the synthesis of an outcome was miss-
ing data that were not/partially reported, because the
non-/partially reported outcome was not specified in the
RoB table. In the remaining 79 reviews, few included any
statement in either the main text (24/79 [30 %]), abstract
(11/63 [17 %]) or Summary of Findings table (9/47 [19 %])
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that data were missing from a synthesis (Table 4; see
individual comments of Additional file 1: Table S3). How-
ever, review authors were more likely to acknowledge
that data were missing from a synthesis in the main
text if the outcome was a primary review outcome
(42 % vs 7 %; P = 0.0014). Use of a statistical method to
explore whether a meta-analysis was robust to outcome
non-reporting bias was not reported in any review.
Discussion
Of 8434 studies included in 586 Cochrane reviews, 53 %
were rated at low risk, 34 % were rated at unclear risk
and 13 % were rated at high risk of bias due to selective
reporting. We classified the reasons for high-risk judge-
ments into nine categories. The most common reason
was concern about outcome non-reporting bias (i.e. non-/
partial reporting of at least one outcome). Few studies
were rated at high risk because of concerns about bias in
selection of the reported result (e.g. reporting of only a
subset of measurements, analysis methods or subsets of
the data that were pre-specified). Review authors often
specified in RoB tables the study outcomes that were
not reported (84 % of studies), but less frequently speci-
fied the outcomes that were partially reported (61 % of
studies), or which were concerning for another reason
(49 %). At least one study was rated at high risk of out-
come non-reporting bias in 31 % of reviews. In a random
sample of these reviews, only 30 % incorporated this infor-
mation when interpreting results, by acknowledging that
Table 2 Frequency of reasons for judgements of high risk of
selective reporting bias
Reason Number (%a) of
1055 studies
Concerns about outcome non-reporting bias 819 (78)
Not all of the study’s pre-specified outcomes have
been reported
387 (37)
One or more outcomes of interest in the review
are partially reported so that they cannot be
entered in a meta-analysis
364 (35)
The study report fails to include results for a key
outcome that would be expected to have been
reported for such a study
188 (18)
Concerns about the documents available for
assessment (e.g. no protocol was available or the
only available report is a conference abstract)
59 (6)
Concerns about reporting of only a subset of
measurements, analysis methods or subsets of
the data that were pre-specified (e.g. data were
reported for only some of the pre-specified time
points)
58 (6)
Concerns about post-hoc reporting of outcomes,
measurements, analysis methods or subsets of the
data (e.g. one or more reported outcomes were not
pre-specified in a protocol or trial registry)
56 (5)
Concerns about how outcome data were analysed
(e.g. a continuous/ordinal outcome was
dichotomised or adjusted effect estimates were not
reported)
28 (3)
Concerns about discrepant reporting (e.g. outcome
data differed across multiple reports for a particular
study)
9 (1)
Other concerns (e.g. only adverse events occurring
in at least 5 % of participants were reported, trialists
emphasised statistically significant results even
though these were less relevant/secondary
outcomes)
31 (3)
Concerns that are not relevant to the selective
reporting domain (e.g. not all randomised
participants were analysed, baseline data were not
reported, blinding of participants was unclear)
73 (7)
Unclear reason (e.g. stated that “All pre-specified
outcomes were reported” or no reason stated)
69 (7)
aPercentages do not sum to 100 as some trials had more than one reason for
a high-risk judgement. Review authors stated one reason in the majority of
cases (817/1055, 77 %), two reasons for 209/1055 (20 %) studies and three
reasons for 29/1055 (3 %) studies
Table 3 Characteristics of the random sample of reviews with
at least one included study rated at high risk of outcome non-
reporting bias
Characteristics Number (%), of
n = 100
Number of included studies
Total number of studies included in review,
median (IQR)
13 (7–32)
Number of studies per review at high risk of
outcome non-reporting bias, Median (IQR)
2 (1–5)
Percentage of studies per review at high risk of
outcome non-reporting bias, Median (IQR)
20 (11–39)
High risk outcome(s) stated in the risk of bias table
One non-/partially reported outcome clearly
specified
27 (27)
More than one non-/partially reported outcome
clearly specified
52 (52)
No outcome specified (e.g. only stated that “Some
outcomes were not reported”)
21 (21)
Reviewer-perceived importance of high-risk
outcome(s)
At least one was a primary review outcome 52 (66)a
All were secondary review outcomes 27 (34)a
Synthesis of high-risk outcome(s)
At least one outcome was synthesised in a meta-
analysis (based on data from studies that
completely reported the outcome)
51 (65)a
All outcome(s) were synthesised/summarised
narratively
28 (35)a
Location in the review where the synthesis of at least
one high-risk outcome was reported
Main text 79 (100)a
Abstract 63 (80)a
Summary of Findings table 47 (59)a
aThe denominator is 79 because 21 reviews did not specify in the risk of bias
table the outcome that was not/partially reported
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the synthesis of an outcome was missing data that were
not/partially reported.
A strength of our study is that we examined a large
cohort of Cochrane reviews, which comprised all reviews
published during a specific period (rather than a non-
randomly selected sample). Further, collection of data on
judgements (low/unclear/high) and supporting text in
RoB tables was automated by Cochrane database man-
agers, which removed the potential for errors due to
manual data extraction. There are also some limitations.
Only one author classified reasons for the judgements of
high risk of selective reporting bias, so there is potential
for misclassification. However, category labels for many
reasons were re-evaluated on multiple occasions, as
modifications to categories were made whenever new
examples were encountered; this may have reduced the
potential for misclassification. Further, it is possible
that some studies we examined were included in more
than one of the included reviews. Therefore, our esti-
mates of the number of studies at low/unclear/high risk
of bias may have double-counted some studies. How-
ever, given that Cochrane strives to produce reviews
addressing mutually exclusive questions, we suspect
that the number of overlapping studies is low. Finally,
we only examined Cochrane reviews so our findings
may not generalise to non-Cochrane reviews which use
the RoB tool.
The percentage of Cochrane reviews in our sample with
at least one study suspected of outcome non-reporting
bias (31 %) is lower than that observed in previous re-
search. This bias was suspected in at least one study in
34 % of 283 Cochrane reviews published between 2006
and 2007 [2], but only the primary outcome in each re-
view (rather than all outcomes) was assessed. When all
outcomes were assessed in 46 Cochrane cystic fibrosis
reviews, 100 % of reviews included at least one study
suspected of outcome non-reporting bias [17]. Rather
than use the risk of bias assessments by Cochrane re-
viewers, both investigations used a 9-point classification
system to assess studies (ORBIT classification [2, 18]), and
involved methodologists in the assessment. It is possible
that ours is an underestimate of the true extent of the
problem of outcome non-reporting bias, because of
variation in how review authors interpret the guidance
for the RoB tool, and in how Cochrane Review Groups
enforce this guidance. In a 2014 survey of managing
and coordinating editors of 42 Cochrane Review
Groups, only 57 % expected review authors to search
for trial protocols as a step in performing the assessment,
and only 23 % considered their review authors to be mod-
erately or largely competent in performing assessments
[19]. Therefore, estimates of the frequency of biased
studies based on routinely collected risk of bias assess-
ments by Cochrane reviewers should be interpreted
with caution [20].
Many of the reasons for high risk of bias judgements
were poorly articulated in the RoB tables. For example,
statements such as “Some outcomes were partially
reported” (encountered in 39 % of studies) make it
impossible for readers to know which outcomes to in-
terpret with caution unless they retrieve the primary
study report. Further, statements suggesting concern
about how outcome data were analysed (e.g. “trialists
reported change from baseline values” or “trialists re-
ported unadjusted effect estimates”) are incomplete; it
is unclear if review authors were concerned that the de-
cision to report these effect estimates was data-driven
or because they find such analytic strategies inappropri-
ate in general. Also, rating a study at high risk of bias
because “no protocol was available” means readers are
left to guess whether the review authors suspect some
outcomes are missing from the published report, or
that the reported outcome data have been selected on
the basis of the results, or both these reasons, or nei-
ther. Review authors often failed to acknowledge that a
synthesis of an outcome was missing data that were
not/partially reported, and this may have occurred for
several reasons. It is possible that review authors be-
lieve that completing RoB tables is sufficient, without
considering that readers may not refer to these tables
[21]. Authors may believe readers are likely to ignore
any narrative description of the risk of outcome non-
Table 4 Number of reviews which acknowledged that the synthesis of an outcome was missing data that were not/partially
reported
Location of statement that
data was missing from the
synthesis
Type of review outcome Chi-squared test
P valuebAny outcome,
number (%) of reviewsa
Primary outcomes,
number (%) of reviews
Secondary outcomes,
number (%) of reviews
Main text 24/79 (30) 22/52 (42) 2/27 (7) 0.0014
Abstract 11/63 (17) 9/51 (18) 2/12 (17) 0.9358
Summary of Findings table 9/47 (19) 7/35 (20) 2/12 (17) 0.8001
aThe denominators reflect the number of reviews for which the assessment was possible. For example, only 63 abstracts were assessed because the outcome that
was not/partially reported in some studies was only described in the abstract of 63 reviews
bDifference in the proportion of reviews with acknowledgement that data were missing from the synthesis of an outcome when the outcome was considered
primary versus when the outcome was considered secondary by the review authors
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reporting bias and instead just focus on the synthesised
effect estimate. Further, the Cochrane Handbook cur-
rently does not provide a framework to guide review
authors to consider the extent of missing outcome data
within a synthesis, and whether its absence is likely to
have biased the result (that is, the corresponding risk of
bias in the systematic review effect estimate).
Developers of future risk of bias tools could address
the problems discussed thus far by adopting the follow-
ing suggestions. We believe that assessments should be
directed at specific results rather than at the study as a
whole, to account for that fact that risk of bias may not
be the same for each result. Further, we propose that
tools designed to assess the risk of bias in effect esti-
mates of individual primary studies should assess bias
in selection of the reported result but not outcome
non-reporting bias. Outcome non-reporting bias could
instead be appraised using a different mechanism, such
as a tool to assess the risk that a synthesis (rather than
an individual primary study) is affected by reporting
biases; this tool could also address the risk of bias due
to unpublished studies (“publication bias”) [12]. We are
currently involved in projects to develop a reporting
bias tool for systematic reviews, and to revise the
Cochrane risk of bias tool for randomised trials in line
with the suggestions outlined above. We anticipate that
these initiatives will help review authors derive more
appropriate conclusions about the benefits and harms
of interventions.
Conclusions
Our audit of user practice in Cochrane reviews suggests
that the assessment of selective reporting in the current
RoB tool does not work well. It is not always clear which
outcomes were selectively reported or what the corre-
sponding risk of bias is in the synthesis with missing out-
come data. New tools that will make it easier for reviewers
to convey this information are being developed.
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